Begin main content

voretigene neparvovec

Last Updated: March 25, 2020
Result type: Reports
Project Number: SR0643-000
Product Line: Common Drug Review

Generic Name: voretigene neparvovec

Brand Name: Luxturna

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Vision loss, inherited retinal dystrophy

Manufacturer Requested Reimbursement Criteria1: ​As per Health Canada anticipated label

Submission Type: New

Project Status: Pending

Call For Patient Input: March 25, 2020

Patient Input Closed: May 14, 2020

Anticipated Date: April 23, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback